Lou Schizas Medicure Inc MPH-X WEAK BUY Oct 29, 2003

Just improved their cash position through a share sale. Have been approved in Canada to begin phase two trials for a hypertension product as well as being in phase two for their lead product. Well-positioned. Some technical concerns.

Lou Schizas

Unknown

Unlock Rating

$1.480

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TRADE

Up 155% year-to-date and 12% on a 52-week basis. It's topping out now, finding a base. Having good support in the $1.50/1.60 range. Has about $10 million in cash, which is sufficient to get them through 2005. No revenue. Good partnerships.

COMMENT

$0.33 of earnings in 2016 is expected to more than double. Roughly a median estimate of $.82 against $10.45, about a 13X PE multiple. It has existing drugs with sales related to that.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Lou Schizas Medicure Inc MPH-X WEAK BUY Oct 29, 2003

You might be interested:

Medicure Inc(MPH-X)

Medicure Inc(MPH-X)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights